Andrew Perry1, Francis Loh2, Luigi Adamo1, Kathleen W Zhang1, Elena Deych1, Randi Foraker2, Douglas L Mann1. 1. Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America. 2. Institute for Informatics, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Abstract
BACKGROUND: Patients with heart failure (HF) with recovered ejection fraction (HFrecEF) are a recently identified cohort that are phenotypically and biologically different from HFrEF and HFpEF patients. Whether there are unique phenotypes among HFrecEF patients is not known. METHODS: We studied all patients at a large medical center, who had an improvement in LVEF from ≤ 35% to ≥ 50% (LVrecEF) between January 1, 2005 and December 31, 2013. We identified a set of 11 clinical variables and then performed unsupervised clustering analyses to identify unique clinical phenotypes among patients with LVrecEF, followed by a Kaplan-Meier analysis to identify differences in survival and the proportion of LVrecEF patients who maintained an LVEF ≥ 50% during the study period. RESULTS: We identified 889 patients with LVrecEF who clustered into 7 unique phenotypes ranging in size from 37 to 420 patients. Kaplan-Meier analysis demonstrated significant differences in mortality across clusters (logrank p<0.0001), with survival ranging from 14% to 87% at 1000 days, as well as significant differences in the proportion of LVrecEF patients who maintained an LVEF ≥ 50%. CONCLUSION: There is significant clinical heterogeneity among patients with LVrecEF. Clinical outcomes are distinct across phenotype clusters as defined by clinical cardiac characteristics and co-morbidities. Clustering algorithms may identify patients who are at high risk for recurrent HF, and thus be useful for guiding treatment strategies for patients with LVrecEF.
BACKGROUND:Patients with heart failure (HF) with recovered ejection fraction (HFrecEF) are a recently identified cohort that are phenotypically and biologically different from HFrEF and HFpEF patients. Whether there are unique phenotypes among HFrecEF patients is not known. METHODS: We studied all patients at a large medical center, who had an improvement in LVEF from ≤ 35% to ≥ 50% (LVrecEF) between January 1, 2005 and December 31, 2013. We identified a set of 11 clinical variables and then performed unsupervised clustering analyses to identify unique clinical phenotypes among patients with LVrecEF, followed by a Kaplan-Meier analysis to identify differences in survival and the proportion of LVrecEF patients who maintained an LVEF ≥ 50% during the study period. RESULTS: We identified 889 patients with LVrecEF who clustered into 7 unique phenotypes ranging in size from 37 to 420 patients. Kaplan-Meier analysis demonstrated significant differences in mortality across clusters (logrank p<0.0001), with survival ranging from 14% to 87% at 1000 days, as well as significant differences in the proportion of LVrecEF patients who maintained an LVEF ≥ 50%. CONCLUSION: There is significant clinical heterogeneity among patients with LVrecEF. Clinical outcomes are distinct across phenotype clusters as defined by clinical cardiac characteristics and co-morbidities. Clustering algorithms may identify patients who are at high risk for recurrent HF, and thus be useful for guiding treatment strategies for patients with LVrecEF.
Authors: Paaladinesh Thavendiranathan; Andrew D Grant; Tomoko Negishi; Juan Carlos Plana; Zoran B Popović; Thomas H Marwick Journal: J Am Coll Cardiol Date: 2012-11-28 Impact factor: 24.094
Authors: Luigi Adamo; Andrew Perry; Eric Novak; Majesh Makan; Brian R Lindman; Douglas L Mann Journal: Circ Heart Fail Date: 2017-06 Impact factor: 8.790
Authors: Josep Lupón; Carles Díez-López; Marta de Antonio; Mar Domingo; Elisabet Zamora; Pedro Moliner; Beatriz González; Javier Santesmases; Maria I Troya; Antoni Bayés-Genís Journal: Eur J Heart Fail Date: 2017-04-06 Impact factor: 15.534
Authors: Valentina Kutyifa; Axel Kloppe; Wojciech Zareba; Scott D Solomon; Scott McNitt; Slava Polonsky; Alon Barsheshet; Bela Merkely; Bernd Lemke; Vivien Klaudia Nagy; Arthur J Moss; Ilan Goldenberg Journal: J Am Coll Cardiol Date: 2013-03-05 Impact factor: 24.094